The Taiwanese biopharmaceutical industry has entered a pivotal "showdown year" in 2026. At least 10 blockbuster candidates are moving into the international commercial phase, with the number of drug licenses expected to hit a record high.

• The Shift to Commercialization: Analysts view this as a transition from "clinical validation" to "global market entry." Companies are moving away from traditional out-licensing models toward building autonomous global sales teams for niche and orphan indications.
• Key Players & Pipelines:
• PharmaEssentia: Following the success of Ropeg in Polycythemia Vera (PV)—which pushed annual revenue past NT$10 billion—the company is now eyeing a second indication for Essential Thrombocythemia (ET).
• Belite Bio (Subsidiary of LinBios): Its lead candidate, LBS-008, is positioned to become the world's first treatment for Adolescent Stargardt Disease. Chairman Dr. Tom Lin has gained significant international attention (including two Fortune features) for this first-in-class potential. The company plans to submit its NDA to the U.S. FDA in H1 2026.
• Medigen Vaccine Biologics (MVC): Holding a 90% domestic market share for its Enterovirus vaccine, MVC is awaiting regulatory approval in Vietnam. To support Southeast Asian demand, the company is investing NT$871 million in a new production line in Hsinchu.
• EirGenix: Progress in Pertuzumab (HER2+ breast cancer biosimilar) and 505(b)(2) new formulations are also under close watch. EirGenix has received positive feedback from the FDA and EMA, seeking a Phase III waiver based on existing PK/analytical comparability data to accelerate its launch.

Resource: 台灣新藥2026迎決戰年 至少10項重磅新藥將進入國際賽局